Future of Therapy for Inborn Errors of Immunity
Crossref DOI link: https://doi.org/10.1007/s12016-021-08916-8
Published Online: 2022-01-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Perez, Elena
Text and Data Mining valid from 2022-01-12
Version of Record valid from 2022-01-12
Article History
Accepted: 23 November 2021
First Online: 12 January 2022
Declarations
:
: Not applicable.
: Consultancy work for Takeda, Grifols, CSL Behring; Speaker bureau for Takeda, Genentech, CSL Behring.